Inhibition of hypoxia-inducible transcription factor complex with designed epipolythiodiketopiperazine

Biopolymers. 2011 Jan;95(1):8-16. doi: 10.1002/bip.21550.

Abstract

Designed small molecule inhibitors of hypoxia-inducible gene expression have potential to become new research tools for molecular biology, genetics and serve as leads to new therapeutics. We report design, synthesis evaluation of biological activity, and a preliminary mechanistic study of epipolythiodiketopiperazine (ETP) transcriptional antagonist that targets the interaction between the C-terminal transactivation domain (C-TAD) of hypoxia-inducible factor 1α (HIF-1α) and cysteine-histidine rich region (CH1) of transcriptional coactivator p300/CBP. Our results indicate that in cultured cells synthetic ETP 3 disrupts the structure and function of this complex in a dose-dependent manner, resulting in rapid downregulation of hypoxia-inducible gene expression.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Gene Expression Regulation / drug effects*
  • Humans
  • Hypoxia-Inducible Factor 1 / antagonists & inhibitors*
  • Molecular Sequence Data
  • Piperazines / chemical synthesis
  • Piperazines / chemistry
  • Piperazines / pharmacology*

Substances

  • Hypoxia-Inducible Factor 1
  • Piperazines
  • epipolythiodiketopiperazine